Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs RMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

RMD Overall Winner 6-Pillar Tally: DCTH 3 – 3 RMD Matrix Metrics: DCTH 2 – 8 RMD

As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas RMD carries 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin).

  • Growth vs. Quality Trade-Off: RMD earns the overall head-to-head edge with a stronger Unified Composite Score (59.0/100 HOLD vs. DCTH 35.9/100 SELL) and 0.41β · 43% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs RMD
DCTH NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
RMD NYSE Head-to-Head Winner
ResMed Inc.
Surgical & Medical Instruments & Apparatus
$239.34
-0.08% 1D
Market Cap $33.6B
TTM Revenue $5.73B
Forward P/E 19.8x
Beta / 30D Vol 0.41β · 43% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 62.0 Fund 59.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 54.8 · SMA20: $241.92 · SMA50: $232.43

6-Pillar Scorecard Institutional Category Breakdown (DCTH 3 – 3 RMD)

Columns: Metric · DCTH · RMD
1. Valuation Multiples RMD
Forward P/E N/M 19.8x
Trailing P/E 133.6x 21.8x
PEG Ratio 1.60x 1.28x
EV / Revenue 6.3x 5.8x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +5.9%
Earnings Growth (YoY) +750.0% +23.2%
TTM Revenue (USD) $110M $5.73B
Market Cap $743.8M $33.6B
3. Profitability & Quality RMD
Gross Margin 87.6% 61.8%
Operating Margin 5.2% 34.0%
Net Profit Margin 6.0% 27.8%
Return on Equity (ROE) 5.4% 26.4%
4. Balance Sheet & Cash Flow RMD
Cash Generation (TTM) $20M $1.59B
Cash Flow Margin 18.3% 27.7%
Net Cash / Leverage $53M Net Cash $400M Net Cash
Dividend Yield None (0.00%) 1.03%
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT CONSOLIDATION
Current IV / %ile 109.3% (43rd %ile) 28.2% (22nd %ile)
Put/Call OI Skew 0.11x (Call-Skewed) 2.00x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) 27.8% of Rev ($1.59B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (2) vs RMD (8)
Institutional Metric DCTH RMD Criterion Row Edge
Market Capitalization
Scale
$743.8M $33.6B Larger Scale RMD
Trailing P/E Ratio
Valuation
133.6x 21.8x Lower Multiple RMD
Forward P/E Ratio
Valuation
N/M 19.8x Lower Multiple RMD
Revenue Growth (YoY)
Growth
+70.7% +5.9% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% 34.0% Higher Margin RMD
Net Profit Margin
Profitability
6.0% 27.8% Higher Margin RMD
Return on Equity (ROE)
Capital Efficiency
5.4% 26.4% Higher ROE RMD
52-Week Range Position
Momentum
80% ($8–$23) 61% ($180–$278) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 0.41β · 43% Vol Lower Realized Risk RMD
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 59.0 / 100 (HOLD) Higher Composite RMD
Trailing 12M Revenue (USD)
Operating Scale
$110M $5.73B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 61.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev 1.28x PEG · 5.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) $1.59B ($400M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +39.61 pp
DCTH: +39.77% · RMD: +0.16%
3M Horizon DCTH +7.93 pp
DCTH: +16.73% · RMD: +8.8%
6M Horizon DCTH +60.22 pp
DCTH: +77.46% · RMD: +17.24%
1Y Horizon DCTH +133.63 pp
DCTH: +128.57% · RMD: -5.06%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue RMD Revenue DCTH Op. Margin RMD Op. Margin Margin Leader
FY2019 N/A $2.61B N/A 22.2% RMD
FY2020 N/A $2.96B N/A 27.4% RMD
FY2021 $0M $3.20B -690.0% 28.3% RMD
FY2022 $0M $3.58B -1245.1% 28.0% RMD
FY2023 $0M $4.22B -1849.0% 26.8% RMD
FY2024 $40M $4.69B -33.4% 28.2% RMD
FY2025 $90M $5.15B 0.8% 32.7% RMD
FY2026 N/A $5.65B N/A 33.4% RMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RMD CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 28.2%
IV Percentile 22nd %ile
Put/Call OI Skew 2.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
RMD Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $33.6B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 27.8% of Rev ($1.59B)
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs RMD Key Questions & Quantitative Answers

As of Nov 16, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas RMD carries 59.0/100 (HOLD) at $239.34 (19.8x Forward P/E, 34.0% operating margin). Growth vs. Quality Trade-Off: RMD earns the overall head-to-head edge with a stronger Unified Composite Score (59.0/100 HOLD vs. DCTH 35.9/100 SELL) and 0.41β · 43% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with RMD at +5.9% YoY revenue growth and +23.2% YoY earnings growth on $5.73B TTM revenue (61.8% gross margin, 34.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), DCTH cumulative revenue shifted +125.0% while RMD shifted +116.5%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus 27.8% of Rev ($1.59B) (0 disclosures) for RMD.

RMD screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas RMD trades at 19.8x Forward P/E, 21.8x Trailing P/E, 1.28x PEG, and 5.8x EV/Revenue (27.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus RMD (26.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, RMD carries 28.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.41β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.